Raspa is a cutting-edge biopharmaceutical firm focused on improving healthcare through technological innovation and scientific advancements.
Beginning at one end of the spectrum, Raspa is currently targeting the raw materials of drugs, namely Active Pharmaceutical Ingredients. Over the years, we would be focusing our efforts towards the development of novel formulations, digital therapeutics, and precision medicine to redefine and reinvent the entire drug value chain to make healthcare more affordable, accessible, and sustainable.
To reduce the cost of treatment for cancer and other severe diseases through technological innovation across value chain.
Patients and their wellbeing form the cornerstone of everything that we do. We believe that value-based innovation keeping the patients’ needs and wellbeing in mind can bring about a definitive change, making quality treatment for cancer and rare diseases affordable and accessible.
An innovation is as valuable as its application. The use of AI, ML, automation, and green chemistry are some of the ways through which we can introduce process and productivity optimization throughout our value chain, thereby reducing costs and creating a tangible impact on the lives of the patients.
At Raspa, we have an ambitious goal to be carbon neutral by 2028 and carbon negative by 2036. Sustainability, however, is not restricted to environment conservation alone but extends to all other stakeholders namely consumers, employees, and shareholders. Stakeholder sustainability and ESG (Environment, Social, and Governance) compliance therefore form the cornerstone of everything that we do here at Raspa- for a “sustainable organization is a stronger organization”.